QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.104.009282v1 67/6/2040    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Free, R. B. Articles by McKay, D. B. Search for Related Content PubMed PubMed Citation Articles by Free, R. B. Articles by McKay, D. B.

Expression of Native 34* Neuronal Nicotinic Receptors: Binding and Functional Studies Investigating Turnover of Surface and Intracellular Receptor Populations

Division of Pharmacology, College of Pharmacy (R.B.F., S.B.M., D.B.M.), and Department of Neuroscience, College of Medicine and Public Health (R.T.B.), The Ohio State University, Columbus, Ohio; and Department of Molecular Genetics and Microbiology, The University of Texas at Austin, Austin, Texas (P.D.G.)

Several pathological conditions involve alterations in expression of neuronal nicotinic acetylcholine receptors (nAChRs). Although some studies have addressed processes involved with muscle nAChR expression, knowledge of the regulation of neuronal nAChRs is particularly sparse. The following studies were designed to investigate cellular mechanisms involved with expression of neuronal 34* nAChRs. Catecholamine secretion assays and receptor binding studies coupled with receptor alkylation were used to study the nAChR regulation and turnover. Alkylation of adrenal nAChRs results in a rapid and complete loss of receptor-mediated neurosecretion and surface [³H]epibatidine binding sites. After alkylation, both neurosecretory function and nAChR binding slowly (24–48 h) return to prealkylation levels. When cells are treated with the protein synthesis inhibitor puromycin, after alkylation, receptor-mediated neurosecretion does not recover. Long-term treatment (24–48-h) with puromycin, in the absence of alkylation, results in a slow, time-dependent shift to the right, followed by a downward shift, in the nicotine concentration-response curve, documenting a disappearance of surface nAChRs. Puromycin treatment alone also results in a loss to both surface and intracellular [³H]epibatidine binding sites. nAChR 4 subunit levels are significantly decreased after treatment with puromycin. These data support a constitutive turnover of adrenal 34* nAChRs, requiring continual de novo synthesis of new receptor protein.

Received for publication November 23, 2004.

Accepted for publication March 16, 2005.

Address correspondence to: Dr. Dennis B. McKay, Division of Pharmacology, College of Pharmacy, The Ohio State University, 500 West 12th Ave., Columbus, OH 43210. E-mail: mckay.2{at}osu.edu